SPP1 and non-small cell lung carcinoma: Beside breast cancer, pan-osteopontin levels have been associated with treatment responses of prostate cancer to taxanes/androgen deprivation [17], of lung cancer (NSCLC) to carboplatin/paclitaxel [18], and of colorectal cancer to FOLFIRI-bevacizumab [19] (as osteopontin interacts with VEGF in multiple ways [20] it would be expected to affect the response to bevacizumab).